Craig Thomas

City:

Gaithersburg, Maryland

Country:

United States

Published Applications:

Last publication date:

2023-10-19

Top Assignees for applications by Craig Thomas

The entities that hold a legal rights for patent applications filed by inventor Thomas Craig:

The United States of America, as represented by the Secretary, Department of Health and Human Services 5 Bethesda, MD United States
University of Maryland ,Baltimore 3 Baltimore, MD United States
United States of America, as represented by the Secretary, Department of Health and Human Services 1 Washington, DC United States
The United States of America, as represented by the Secretary, Department of Health and Human Services 1 Washington, DC United States
The Gov. of the U.S.A., as represented by the Secretary, Dept of Health And Human Services 1 Rockville, MD United States
The United States of America, as represented by the Secretary, Department of Health and Human Serv 1 Bethesda, MD United States

Recent patent applications by Thomas Craig

Craig Thomas from Gaithersburg, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2023-10-19

US20230331655A1

Chemistry; metallurgy

HYDROXYNORKETAMINE COMPOUNDS AND METHODS OF USE THEREOF

#2 | 2023-06-22

US20230192594A1

Chemistry; metallurgy

CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE

#3 | 2022-12-15

US20220396572A1

Chemistry; metallurgy

Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type a receptors as fast acting treatment for depression and mood disorders

#4 | 2021-05-13

US20210139411A1

Chemistry; metallurgy

Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine

#5 | 2020-06-25

US20200199119A1

Chemistry; metallurgy

Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type A receptors as fast acting treatment for depression and mood disorders

#6 | 2019-05-09

US20190135732A1

Chemistry; metallurgy

Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine

#7 | 2019-03-21

US20190083420A1

Human necessities

METHODS OF USING (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE IN THE TREATMENT OF DEPRESSION, ANXIETY, ANHEDONIA, FATIGUE, SUICIDAL IDEATION, AND POST TRAUMATIC STRESS DISORDERS

#8 | 2014-09-04

US20140249181A1

Human necessities

Tropolone compounds for treating or preventing retroviral infection

#9 | 2012-11-22

US20120294843A1

Chemistry; metallurgy

Caspase inhibitors

#10 | 2008-07-31

US20080182805A1

Chemistry; metallurgy

O-GlcNAcase-specific inhibitor and substrate engineered by the extension of the N-Acetyl moiety

InventorID:

896794 ⎘